Jeffrey S. Parkin

Array ( [id] => 7082701 [patent_doc_number] => 20050048081 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2005-03-03 [patent_title] => 'Immunogenic compositions comprising DAL/DAT double mutant, auxotrophic attenuated strains of listeria and their mehods of use' [patent_app_type] => utility [patent_app_number] => 10/660194 [patent_app_country] => US [patent_app_date] => 2003-09-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 17 [patent_figures_cnt] => 17 [patent_no_of_words] => 11182 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0048/20050048081.pdf [firstpage_image] =>[orig_patent_app_number] => 10660194 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 376818 [patent_doc_number] => 07311916 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2007-12-25 [patent_title] => 'Methods of eliciting broadly neutralizing antibodies targeting HIV-1 gp41' [patent_app_type] => utility [patent_app_number] => 10/660206 [patent_app_country] => US [patent_app_date] => 2003-09-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 11 [patent_no_of_words] => 15087 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 77 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/07/311/07311916.pdf [firstpage_image] =>[orig_patent_app_number] => 10660206 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 7220446 [patent_doc_number] => 20050260717 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2005-11-24 [patent_title] => 'Double transdominant fusion gene and protein' [patent_app_type] => utility [patent_app_number] => 10/648954 [patent_app_country] => US [patent_app_date] => 2003-08-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 8 [patent_no_of_words] => 4367 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 9 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0260/20050260717.pdf [firstpage_image] =>[orig_patent_app_number] => 10648954 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 220876 [patent_doc_number] => 07608422 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2009-10-27 [patent_title] => 'Simian immunodeficiency virus (SIV) molecular clone encoding mutant gag gene lacking inhibitory/instability regions' [patent_app_type] => utility [patent_app_number] => 10/644027 [patent_app_country] => US [patent_app_date] => 2003-08-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 45 [patent_figures_cnt] => 45 [patent_no_of_words] => 15809 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 27 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/07/608/07608422.pdf [firstpage_image] =>[orig_patent_app_number] => 10644027 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 5693718 [patent_doc_number] => 20060153865 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2006-07-13 [patent_title] => 'Antigenic peptides' [patent_app_type] => utility [patent_app_number] => 10/529885 [patent_app_country] => US [patent_app_date] => 2003-08-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20525 [patent_no_of_claims] => 45 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0153/20060153865.pdf [firstpage_image] =>[orig_patent_app_number] => 10529885 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 7464124 [patent_doc_number] => 20040053335 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2004-03-18 [patent_title] => 'Method for detecting prions' [patent_app_type] => new [patent_app_number] => 10/641663 [patent_app_country] => US [patent_app_date] => 2003-08-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 4 [patent_no_of_words] => 11868 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 60 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0053/20040053335.pdf [firstpage_image] =>[orig_patent_app_number] => 10641663 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 7288680 [patent_doc_number] => 20040109876 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2004-06-10 [patent_title] => 'Vaccine composition, HIV-infection suppression factor and method for the vaccination against HIV' [patent_app_type] => new [patent_app_number] => 10/634743 [patent_app_country] => US [patent_app_date] => 2003-08-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 15 [patent_figures_cnt] => 15 [patent_no_of_words] => 8124 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 6 [patent_words_short_claim] => 14 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0109/20040109876.pdf [firstpage_image] =>[orig_patent_app_number] => 10634743 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 484656 [patent_doc_number] => 07217418 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2007-05-15 [patent_title] => 'Multivalent dengue virus vaccine' [patent_app_type] => utility [patent_app_number] => 10/626315 [patent_app_country] => US [patent_app_date] => 2003-07-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 19 [patent_no_of_words] => 20443 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 130 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/07/217/07217418.pdf [firstpage_image] =>[orig_patent_app_number] => 10626315 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 7361844 [patent_doc_number] => 20040014701 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2004-01-22 [patent_title] => 'Inhibiting retrotransposon and retroviral integration by targeting the atm pathway' [patent_app_type] => new [patent_app_number] => 10/296845 [patent_app_country] => US [patent_app_date] => 2003-07-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 14 [patent_no_of_words] => 12572 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 8 [patent_words_short_claim] => 22 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0014/20040014701.pdf [firstpage_image] =>[orig_patent_app_number] => 10296845 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 281619 [patent_doc_number] => 07553618 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2009-06-30 [patent_title] => 'Method for determining human immunodeficiciency virus type 1 (HIV-1) hypersusceptibility to the protease inhibitor amprenavir' [patent_app_type] => utility [patent_app_number] => 10/612600 [patent_app_country] => US [patent_app_date] => 2003-07-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 10 [patent_no_of_words] => 16927 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 158 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/07/553/07553618.pdf [firstpage_image] =>[orig_patent_app_number] => 10612600 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 236070 [patent_doc_number] => 07595050 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2009-09-29 [patent_title] => 'Human IGM monoclonal antibody capable of inducing apoptosis in HIV-infected cells' [patent_app_type] => utility [patent_app_number] => 10/519855 [patent_app_country] => US [patent_app_date] => 2003-06-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 5 [patent_no_of_words] => 3370 [patent_no_of_claims] => 3 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 59 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/07/595/07595050.pdf [firstpage_image] =>[orig_patent_app_number] => 10519855 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6678189 [patent_doc_number] => 20030228329 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2003-12-11 [patent_title] => 'Adenovirus carrying gag gene HIV vaccine' [patent_app_type] => new [patent_app_number] => 10/461030 [patent_app_country] => US [patent_app_date] => 2003-06-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 26 [patent_figures_cnt] => 26 [patent_no_of_words] => 13506 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 42 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0228/20030228329.pdf [firstpage_image] =>[orig_patent_app_number] => 10461030 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 5141349 [patent_doc_number] => 20070003565 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2007-01-04 [patent_title] => 'Use of hab18g/cd147 molecule as target for antiviral antagonists and thus obtained antiviral antagonist' [patent_app_type] => utility [patent_app_number] => 10/556757 [patent_app_country] => US [patent_app_date] => 2003-06-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 3782 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0003/20070003565.pdf [firstpage_image] =>[orig_patent_app_number] => 10556757 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 7252498 [patent_doc_number] => 20040259224 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2004-12-23 [patent_title] => 'Tetravalent Dengue vaccines' [patent_app_type] => new [patent_app_number] => 10/452610 [patent_app_country] => US [patent_app_date] => 2003-06-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 8 [patent_no_of_words] => 32970 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 106 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0259/20040259224.pdf [firstpage_image] =>[orig_patent_app_number] => 10452610 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 7429736 [patent_doc_number] => 20040001845 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2004-01-01 [patent_title] => 'Cytotoxic T-cell epitopes of HIV-1 virus' [patent_app_type] => new [patent_app_number] => 10/442909 [patent_app_country] => US [patent_app_date] => 2003-05-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 6 [patent_no_of_words] => 10548 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 10 [patent_words_short_claim] => 37 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0001/20040001845.pdf [firstpage_image] =>[orig_patent_app_number] => 10442909 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6701107 [patent_doc_number] => 20030223987 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2003-12-04 [patent_title] => 'Immunodeficiency recombinant poxvirus' [patent_app_type] => new [patent_app_number] => 10/441788 [patent_app_country] => US [patent_app_date] => 2003-05-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 129 [patent_figures_cnt] => 129 [patent_no_of_words] => 49293 [patent_no_of_claims] => 42 [patent_no_of_ind_claims] => 10 [patent_words_short_claim] => 4 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0223/20030223987.pdf [firstpage_image] =>[orig_patent_app_number] => 10441788 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 3782 [patent_doc_number] => 07811580 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2010-10-12 [patent_title] => 'Chimeric HIV Env proteins comprising CD4 mini-proteins or CD4 mimetics that are capable of inducing neutralizing antibody responses against cryptic Env epitopes' [patent_app_type] => utility [patent_app_number] => 10/514055 [patent_app_country] => US [patent_app_date] => 2003-05-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 7 [patent_no_of_words] => 23422 [patent_no_of_claims] => 24 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 116 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/07/811/07811580.pdf [firstpage_image] =>[orig_patent_app_number] => 10514055 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 7195446 [patent_doc_number] => 20050164166 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2005-07-28 [patent_title] => 'Identification of novel broadly cross-reactive hiv-1 neutralizing human monoclonal Antibodies' [patent_app_type] => utility [patent_app_number] => 10/512966 [patent_app_country] => US [patent_app_date] => 2003-05-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 6 [patent_no_of_words] => 12825 [patent_no_of_claims] => 87 [patent_no_of_ind_claims] => 12 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0164/20050164166.pdf [firstpage_image] =>[orig_patent_app_number] => 10512966 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 7451512 [patent_doc_number] => 20040010125 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2004-01-15 [patent_title] => 'HIV-2 transmembrane glycoprotein homodimer (gp 80)' [patent_app_type] => new [patent_app_number] => 10/422791 [patent_app_country] => US [patent_app_date] => 2003-04-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 11 [patent_no_of_words] => 13175 [patent_no_of_claims] => 49 [patent_no_of_ind_claims] => 14 [patent_words_short_claim] => 15 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0010/20040010125.pdf [firstpage_image] =>[orig_patent_app_number] => 10422791 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 281926 [patent_doc_number] => 07553926 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2009-06-30 [patent_title] => 'Compositions containing anti-HIV peptides and methods for use' [patent_app_type] => utility [patent_app_number] => 10/421664 [patent_app_country] => US [patent_app_date] => 2003-04-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 21 [patent_figures_cnt] => 24 [patent_no_of_words] => 15135 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 47 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/07/553/07553926.pdf [firstpage_image] =>[orig_patent_app_number] => 10421664 [rel_patent_id] =>[rel_patent_doc_number] =>)